Today: 30 June 2026
Lumentum (LITE) stock drops 7.5% as CAO succession disclosed and Feb. 3 earnings date set
6 January 2026
1 min read

Lumentum (LITE) stock drops 7.5% as CAO succession disclosed and Feb. 3 earnings date set

New York, January 5, 2026, 19:03 EST — After-hours

  • Lumentum shares fell 7.5% on Monday, last trading at $357.05 in after-hours dealings.
  • A late-day SEC filing detailed a chief accounting officer transition tied to the company’s next quarterly report.
  • Lumentum set Feb. 3 for its fiscal second-quarter results and conference call.

Shares of Lumentum Holdings Inc. slid 7.5% to $357.05 on Monday. The stock ranged from $345 to $394.48 and last traded near $357 in after-hours trading, the period after the 4 p.m. close.

The sharp move puts fresh focus on what the optical-components maker says next, with its quarterly update now weeks away. Traders have been leaning heavily on the data-center buildout narrative, and the bar rises quickly when a stock posts outsized swings.

After the bell, Lumentum disclosed in an SEC filing that Chief Accounting Officer Matthew Sepe told the company of his “planned retirement.” The filing said Sepe will remain senior vice president, finance until fall 2026, but will step down as CAO on the later of Feb. 6, 2026 and the filing date of the company’s Form 10-Q quarterly report for the period ended Dec. 27, 2025; the board appointed Eric Chang to take over as CAO on that effective date. SEC

Earlier on Monday, Lumentum said it will release fiscal second-quarter 2026 financial results on Tuesday, Feb. 3, after the market closes, and host an audio webcast at 5 p.m. ET. The company makes optical and photonic products used in telecom, enterprise and data-center networks, and also sells lasers for manufacturing and other applications.

The drop came on a broadly positive session for U.S. equities, with the S&P 500 ending up 0.64%. Optical names were mixed: IPG Photonics gained 2.7% while nLIGHT fell 0.7%, MarketWatch data showed.

On the Street, investors are already sketching the scorecard for Feb. 3. Zacks’ consensus forecast pegs second-quarter fiscal 2026 earnings at $1.40 per share on revenue of about $652.4 million, according to a Nasdaq.com report.

Lumentum’s February update will test whether demand expectations are holding up and whether execution matches the valuation implied by recent trading. Any detail on order momentum and margins will carry extra weight with the next 10-Q filing also approaching.

There is also a downside scenario. Finance leadership changes are not unusual, but they can draw outsized scrutiny when a company is close to reporting and filing its quarterly statements, and they tend to keep volatility elevated in the near term.

For Tuesday’s regular session, traders will watch whether the stock can hold above the $345–$350 area after Monday’s slide. The next clear catalyst is Feb. 3, when Lumentum reports results and hosts its call, followed by the 10-Q filing that triggers the CAO handoff.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • SELLAS Life Sciences (NASDAQ:SLS) Drops 7.77% After 8-K Filing Ahead of REGAL Data
    June 30, 2026, 10:28 AM EDT. SELLAS Life Sciences shares dropped 7.77% to $14.25 on Tuesday after an 8-K showing senior management agreements and as the market waits for Phase 3 REGAL data on galinpepimut-S in AML. The study is approaching a milestone with 78 of 80 survival events, making some investors cautious. The stock recently hit a 52-week high of $15.67, but resistance is holding there with support at the 20-day simple moving average around $8.87. Technicals are flashing overbought with the RSI at 85.19, which could mean sharper pullbacks. SELLAS works on cancer therapies including GPS and CDK9 drugs, tying its shares to updates around leadership moves and clinical trials.
Hyperscale Data (GPUS) stock jumps 20% in premarket as insider buying keeps spotlight on the microcap
Previous Story

Hyperscale Data (GPUS) stock jumps 20% in premarket as insider buying keeps spotlight on the microcap

SpaceX lines up back-to-back Starlink launches from Florida as orbit crowding comes into focus
Next Story

SpaceX lines up back-to-back Starlink launches from Florida as orbit crowding comes into focus

Go toTop